CRISPR/Cas9 โ After Cleavage, DNA Repair Follows
Why Is This Important?
CRISPR/Cas9 enables the targeting of specific DNA sequences via guide RNA and subsequent cleavage by a nuclease. However, the moment Cas9 cleaves its target marks only the initiation of editing, not the final outcome. Depending on how the cell repairs the break, outcomes may include small indels, desired substitutions, large deletions, or complex rearrangements.
Therefore, it is essential to distinguish between cutting efficiency and the proportion of cells with the desired genotype. Relying solely on an average value may obscure results arising from a mixture of different alleles and cellular states.
Target Recognition and Cleavage
The spacer of the guide RNA binds complementarily to the target DNA, while the Cas nuclease recognizes a short adjacent motif known as the PAM. On-target and off-target activities vary depending on the position and number of mismatches and chromatin accessibility. Scores from guide design tools are predictive rankings for candidate selection and do not substitute for actual activity in cells.
Wild-type Cas9 typically generates double-strand breaks. Nickases, high-fidelity variants, and other Cas enzymes alter cleavage mechanisms and PAM requirements; therefore, they cannot be treated as having equivalent performance under the single designation of CRISPR.
Repair Generates Outcomes
NHEJ-mediated repair is rapid but can generate diverse insertions and deletions, making it suitable for creating knockouts that disrupt the coding frame. HDR allows insertion of desired sequences using a donor template; however, its efficiency may be limited due to sensitivity to cell cycle stage, delivery method, and cell type. Because outcome distributions vary by target, relying on validation of a single representative clone is insufficient.
Large deletions, inversions, and translocations between two cleavage sites, as well as chromosome-scale alterations, are also possible. Short amplicon sequencing may fail to amplify large events that disrupt primer-binding sites, potentially yielding false-normal results.
Base editing and prime editing
Base editors typically convert specific nucleotides without inducing double-strand breaks, whereas prime editors utilize a reverse-transcription template to engineer diverse small alterations. These approaches are subject to bystander editing, unwanted indels, RNA/DNA off-target effects, and delivery limitations. Quality control based solely on metrics applicable to Cas9 nuclease outcomes is insufficient.
To enable meaningful comparison of results, it is essential to document the editing modality, editor version, guide and donor sequences, cell type, and delivery method.
Small Experimental Example
Suppose you aim to correct a disease-associated SNV and observe the desired allele at 40% frequency in bulk sequencing. The remaining 60% may contain a mixture of the original allele and various indels, and some cells may have differentially edited alleles on each chromosome. Genotype combinations must be confirmed using single-cell cloning or single-cell genotyping combined with long-range assays.
Edited clones are also validated to ensure restoration of protein function and phenotype, confirming that selective growth has not resulted in the dominance of a specific clone.
Safety and Validation
Targeted sequencing of predicted off-target sites alone cannot exclude genome-wide risks. Unbiased assays, karyotype and genome-wide analyses, and long-term culture stability are combined according to the intended purpose. Ex vivo editing allows cells to be retrieved for testing prior to administration, but entails manufacturing and clonal expansion risks; in vivo editing hinges on delivery and tissue specificity.
Approved specific therapies have been evaluated based on the guide, manufacturing process, target cells, and clinical evidence of a specific product. This does not guarantee the safety of other targets or arbitrary editing designs.
Common Misconceptions
- The on-target read ratio is not the same as the precisely corrected cell fraction.
- A low off-target rate does not imply the absence of large structural variations at the on-target site.
- Knockout does not always guarantee loss of function, as alternative transcripts may remain.
- Editing success is not equivalent to therapeutic efficacy.
Interpretive Caveats
CRISPR outcomes must be assessed for target site specificity, repair outcome, cell-by-cell mosaicism, off-target effects, and functional restoration. This text explains research principles and does not guide decisions regarding the editing of any person or embryo, nor does it inform therapeutic determinations.
Reading in Context
Evidence of functional recovery is linked to the concepts of functional assays and variant interpretation, while the context of how chromatin accessibility affects editing efficiency is connected to ATAC-seq.